HOT off the ECTRIMS Press…2010 ECTRIMS Meeting Coverage

• Caroline says: Take a look at relevant ECTRIMS presentations in this link...all consolidated onto one handy page.
   

• Related Links:
• http://www.medpagetoday.com/MeetingCoverage/ECTRIMS/…

• HOT off the ECTRIMS Press: Copaxone after CIS delays MS onset

  The study reached both its primary and secondary clinical and MRI endpoints, all of which were significantly positive. Earlier initiation of treatment with Copaxone significantly slowed the [...]

  • Caroline says: Most of the CRABS have now been approved to treat a CIS (clinically isolated syndrome). The data are compelling that early initiation after a first incidence of possible MS can delay disease onset.
     
  • Related Links:
  • http://www.marketwatch.com/story/early-initiation-of-treatment-with-copaxone-r-p…
  
  

  • HOT off the ECTRIMS Press: Roche’s ocrelizumab reduces MS relapse rates in mid-stage trial

    The 24-week trial randomised 220 patients to receive one of two doses of ocrelizumab or placebo given at day one and day 15. Data show that the [...]

    • Caroline says: In Phase II trial data presented at ECTRIMS this year, Roche and Biogen's agent ocrelizumab halted MS relapses by an astounding 73%. Ocrelizumab was being studied for rheumatoid arthritis but discontinued due to safety concerns.
       
    • Related Links:
    • http://www.firstwordplus.com/Fws.do?articleid=F2150D7CD79942CEB4A639BAAEA802B5…
    
    

    • HOT off the ECTRIMS Press: Sanofi-Aventis’ teriflunomide reduces MS relapse rates by 31%

      Sanofi-aventis presented results from a late-stage trial of teriflunomide at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress, demonstrating that both doses of [...]

      • Caroline says: According to data presented at this year's ECTRIMS in Sweden, Sanofi's once-daily oral agent, teriflunomide, reduces MS relapses by 31%, with no major safety concerns.
         
      • Related Links:
      • http://www.firstwordplus.com/Fws.do?articleid=770E8580730C4D73916132B895657D80…
      
      

      • HOT off the ECTRIMS Press: Rebif Prefilled Pen

        Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the upcoming introduction of the new device RebiDose(TM), the Rebif(R) single use pre-filled pen, for the [...]

        • Caroline says: I'm actually surprised that this is just coming out now for Rebif. The autoject pre-filled dose pens have been around for years for other MS injectables.
           
        • Related Links:
        • http://www.prnewswire.co.uk/cgi/news/release?id=300836…
        
        

        • HOT off the ECTRIMS Press: Bayhill Therapeutics to Present Correlation of Antibodies with Clinical Response to Treatment with BHT-3009 in MS

          Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA™ platform to develop targeted autoimmune disease treatments, today announced that it will present at the 26th [...]

          • Caroline says: I'm sure there is someone out there who understands this article much better than I do. I know very little about biomarkers. From what I can tell, Bayhill has developed BHT-3009, a targeted therapy for certain MS patients with high-MDP (myelin basic protein) in their blood. Clinical results to date suggest that BHT-3009 reprograms the immune system to tolerize to, rather than attack, the myelin antigens in the central nervous system of MS patients.
             
          • Related Links:
          • http://www.drugs.com/clinical_trials/bayhill-therapeutics-present-correlation-an…
          
          

          • HOT off the ECTRIMS Press: Genzyme’s Campath (alemtuzumab) Treatment Helps MS Patients at 5 Years

            Genzyme Corp.’s Campath cut the risk of relapse in multiple sclerosis patients by 69 percent compared with Merck KGaA’s Rebif after five years, according to a study. [...]

            • Caroline says: Alemtuzumab probably won't be a blockbuster drug, according to this article. Safety is an issue, but once-yearly dosing via infusion sounds good. Better than a pill every day?
               
            • Related Links:
            • http://www.bloomberg.com/news/2010-10-14/genzyme-s-campath-helps-multiple-sclero…
            
            

            • Sanofi’s Teriflunomide Shows Promise for RRMS

              Sanofi-aventis (NYSE:SNY) recently announced clinical success with teriflunomide, the investigational drug it is developing for the treatment of relapsing multiple sclerosis (RMS). This announcement followed a 2-year [...]

              • Caroline says: The oral market for MS continues to widen...Sanofi's teriflunomide for RRMS announced positive results from TEMSO a 2-year trial v. placebo. Full results will be presented at ECTRIMS this year (Oct 2010).
                 
              • Related Links:
              • http://starglobaltribune.com/2010/multiple-sclerosis-new-teriflunomide-treatment…
              
              

              • Hot off the ECTRIMS Press…Alemtuzumab Shows Lasting Benefits in RRMS

                (RTTNews) -  Friday, biotechnology company Genzyme Corp. said that four-year follow-up data from its completed Phase 2 multiple sclerosis trial continued to show durable reductions in relapse rate [...]

                • Caroline says: The possibility of alemtuzumab (Campath) being FDA approved for MS should excite some of you b-cell MS'ers. Genzyme says that four-year follow-up data from its completed Phase 2 MStrial show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab.
                   
                
                

                • Hot off the ECTRIMS Press…Sanofi Oral is Promising

                  LONDON, Sept 11 (Reuters) – Patients given an experimental multiple sclerosis tablet from Sanofi-Aventis showed a significant improvement compared to those on placebo in a mid-stage test, [...]

                  • Caroline says: In the 24-week study, patients receiving teriflunomide experienced a 56% and 81% reduction in cerebral inflammatory lesions compared with those on placebo, as measured by MRI scan. Patients were given two doses and teriflunomide was well tolerated.
                     
                  
                  
                  « Previous Entries